Skip to main content

Jelmyto Disease Interactions

There are 4 disease interactions with Jelmyto (mitomycin).

Major

Antineoplastics (applies to Jelmyto) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. (2002) "Product Information. Methotrexate (methotrexate)." Lederle Laboratories
  2. (2001) "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb
  3. (2001) "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb
  4. (2001) "Product Information. Novantrone (mitoxantrone)." Immunex Corporation
  5. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb
  6. (2001) "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb
  7. (2001) "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)
  8. (2001) "Product Information. Fludara (fludarabine)." Berlex Laboratories
  9. (2001) "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn
  10. (2001) "Product Information. Matulane (procarbazine)." Roche Laboratories
  11. (2001) "Product Information. DTIC-Dome (dacarbazine)." Bayer
  12. (2001) "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn
  13. (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
  14. (2001) "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company
  15. (2001) "Product Information. Hycamtin (topotecan)." SmithKline Beecham
  16. (2001) "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer
  17. (2001) "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb
  18. (2001) "Product Information. Nipent (pentostatin)." Hospira Inc
  19. (2001) "Product Information. Tabloid (thioguanine)." Prasco Laboratories
  20. (2001) "Product Information. Xeloda (capecitabine)." Roche Laboratories
  21. (2022) "Product Information. Alkeran (melphalan)." Glaxo Wellcome
  22. (2001) "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome
  23. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  24. (2001) "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc
  25. (2001) "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn
  26. (2001) "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation
  27. (2010) "Product Information. Jevtana (cabazitaxel)." sanofi-aventis
  28. (2010) "Product Information. Halaven (eribulin)." Eisai Inc
  29. (2021) "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.
View all 29 references
Major

Mitomycin (applies to Jelmyto) bleeding disorders

Major Potential Hazard, High plausibility. Applicable conditions: Coagulation Defect

The use of mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorders, or an increase in bleeding tendency. Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Therapy with mitomycin should be withheld if platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

References

  1. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb
Major

Mitomycin (applies to Jelmyto) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever

Mitomycin induces cumulative, delayed myelosuppression. Neutropenia and thrombocytopenia can occur anytime within eight weeks after initiation of therapy. Anemia occurs less frequently. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended. Therapy with mitomycin should be withheld if white blood cell counts fall below 4000/mm3 and/or platelet counts fall below 100,000/mm3 and subsequent dosages modified based on the nadir of the previous dose.

References

  1. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb
Major

Mitomycin (applies to Jelmyto) renal dysfunction

Major Potential Hazard, High plausibility.

Elevations in BUN and/or serum creatinine have been reported during mitomycin therapy. Therapy with mitomycin should not be administered to patients with serum creatinine > 1.7 mg/dl. Hemolytic Uremic Syndrome (HUS) has been reported during mitomycin therapy. The incidence of HUS appears to be increased in patients receiving total doses of mitomycin > 60 mg. Blood product transfusion may exacerbate the symptoms of HUS. Clinical monitoring of renal function is recommended.

References

  1. (2001) "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb

Jelmyto drug interactions

There are 252 drug interactions with Jelmyto (mitomycin).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer